A short pangenotypic course works only in the population studied: treatment-naive adults without cirrhosis. Before treatment, confirm active infection with HCV RNA, since an antibody test only shows past exposure. Assess for cirrhosis with a simple score such as APRI or FIB-4, or elastography where available. Test for hepatitis B and HIV, and check for interacting drugs. Confirm cure with HCV RNA 12 weeks after the course ends.
- Confirm active infection with HCV RNA before treating.
- Exclude cirrhosis with APRI, FIB-4 or elastography.
- Screen for hepatitis B and HIV co-infection.
- Recheck HCV RNA 12 weeks after treatment to confirm cure.
Why it matters
The shorter course only applies to patients who truly match the trial population.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free